Meeting Banner
Abstract #2247

Dual-modality evaluation of tumour vasculature, morphology and metabolism via Dynamic Susceptibility Contrast MRI and FluoroEthyl Choline-PET using simultaneous PET/MR

Maria Liljeroth 1 , Kjell Erlandsson 2 , Francesco Fraioli 2 , David Thomas 3 , Enrico De Vita 4 , Brian Hutton 2 , Anna Barnes 5 , Simon Arridge 6 , Sebastien Ourselin 7 , and David Atkinson 8

1 Institute of Nuclear Medicine, Metabolism & Experimental Therapeutics, London, London, United Kingdom, 2 Institute of Nuclear Medicine, Metabolism & Experimental Therapeutics, London, United Kingdom, 3 Institute of Neurology, Faculty of Brain Sciences, Brain Repair & Rehabilitation, London, United Kingdom, 4 National Hospital for Neurology and Neurosurgery, Lysholm Department of Neuroradiology, London, United Kingdom, 5 Institute of Nuclear Medicine, Clinical Physics, London, United Kingdom, 6 Faculty of Engineering Science, Dept of Computer Science, London, United Kingdom, 7 Dept of Med Phys & Biomedical Eng, London, United Kingdom, 8 Faculty of Medical Sciences, Div of Medicine, London, United Kingdom

Simultaneous 18FFECho PET and Dynamic Susceptibility Contrast (DSC)/ Dynamic Contrast Enhanced (DCE) MRI has the potential for providing valuable information regarding tumour morphology and aggressiveness, essential for tumour staging. We present data from a conventional EPI perfusion acquisition strategy as well as a dual-echo GRE approach which allows separation of T1 and T2* effects of Gadolinium thus providing inherent rCBV correction and tracer kinetics. Results show elevated rCBV in astrocytoma relative to pineal germinoma. The specificity of 18FFE Cho provides clear outlining of tumourous regions for kinetic evaluation. PET and MRI images are also inherently coregistered using this technique.

This abstract and the presentation materials are available to members only; a login is required.

Join Here